Anesthetizing an Obese Child With Severe OSA: Whose Weight Sets the Dose?
A single patient whose two most relevant numbers, his actual weight and his ideal weight, point toward very different drug doses. The disagreement is about which one should actually govern, and for which drugs specifically — not a single answer that applies uniformly across the whole anesthetic.
Wesley N. is 10, and the sleep study that brought him to today's adenotonsillectomy is the kind of result that makes a pediatric sleep clinic move quickly: an apnea-hypopnea index of 34, severe by any threshold, with oxygen saturation dropping to 82% during his worst obstructive events at home. His tonsils and adenoids, markedly enlarged on exam, are the surgical target and the physiologic cause working in the same direction — remove the obstruction, and the severe OSA driving tonight's admission plan is expected to improve substantially, sometimes dramatically, within weeks. Getting him safely through today's anesthetic, though, means reconciling two numbers that don't point the same direction: his actual body weight of 68 kilograms, and an estimated ideal body weight for his height of roughly 42 kilograms — a gap wide enough that dosing every drug the same way, scaled to one number or the other uniformly, would be wrong for at least some of what he's about to receive.
The pharmacokinetic reason the two numbers diverge by drug is straightforward once stated plainly: fat-soluble drugs distribute into adipose tissue and their volume of distribution scales more closely with total body weight, while drugs whose effect and clearance track more closely with lean tissue and organ perfusion are better dosed nearer ideal body weight, where dosing to actual weight in a child this size risks real overdose. Opioids sit at the sharpest edge of this problem for Wesley specifically, and not only for pharmacokinetic reasons: children with severe OSA have documented heightened opioid sensitivity independent of body size. Brown and colleagues showed this twice at the Montreal Children's Hospital — first retrospectively (Anesthesiology, 2004), where preoperative oxygen saturation nadir predicted how little morphine a child needed, then prospectively (Anesthesiology, 2006) in children stratified at a nadir of 85%. Wesley's own nadir is 82%, which puts him on the more opioid-sensitive side of the line Brown drew, not merely somewhere in a broad at-risk category. That is a central respiratory-depression risk sitting on top of his baseline obstructive physiology, and it is why the AAO-HNS guideline's inpatient-monitoring recommendation for severe pediatric OSA applies to him regardless of how straightforward the surgery is expected to be.
Preoperative anesthetic planning, day of surgery
I want to dose opioids conservatively here, at or below ideal body weight rather than his actual 68 kilograms. This isn't only a fat-versus-lean pharmacokinetic argument — children with severe OSA have documented heightened opioid sensitivity independent of body size, and his own sleep study shows him desaturating to 82% — below the 85% nadir Brown used to separate the more opioid-sensitive children from the rest. Both reasons point the same direction.
If his OSA were mild rather than severe, I'd weigh this differently — the opioid-sensitivity literature is specifically strongest at his severity level, not a blanket statement about every child with any OSA.
I agree on opioids specifically, and I want to sharpen the rest of the plan rather than apply the same conservative instinct uniformly across every drug in this case. Propofol induction dosing should scale closer to a lean-body-weight-adjusted calculation, which for Wesley isn't identical to his ideal body weight — but volatile anesthetic requirements track more closely with actual body composition and shouldn't be under-dosed by the same logic that correctly limits his opioids.
I don't think 'use the lower number' should become the default answer for every drug just because it's clearly right for opioids — that risks under-dosing something else in the name of consistency rather than precision.
Both of you are handling the intraoperative dosing question well, and I want to make sure we don't let a well-calibrated anesthetic create false reassurance about what happens after. His sleep study shows him desaturating to 82% during obstructive events at home, with no surgical support and no anesthetic drugs on board at all — that's his baseline vulnerability, and today's surgery, even done perfectly, doesn't erase it the moment he's extubated.
So: conservative, opioid-sparing, appropriately-weight-based dosing per the plan already laid out, plus mandatory overnight admission with continuous pulse oximetry and a low threshold for escalation — his own numbers are the reason that monitoring plan isn't optional.
Opioid dosing conservative and ideal-body-weight-based given documented OSA-specific opioid sensitivity; propofol induction lean-body-weight-adjusted; volatile maintenance dosed by standard practice; mandatory overnight admission with continuous pulse oximetry per severe-OSA protocol.
Not agreed, and the reason the plan carries an explicit branch point rather than a single expectation:
This dosing and monitoring approach is documented as the team's standard protocol for future severe-OSA adenotonsillectomy patients of similar body habitus.
It would be attributed primarily to his underlying obstructive physiology rather than to dosing error, reinforcing the second anesthesiologist's point that monitoring, not dosing alone, is the real safety lever.
Whether a single simplified weight-based dosing rule (uniformly lower for every drug) would have been safer in practice despite being less pharmacokinetically precise, versus the drug-by-drug approach actually used — the pharmacologist's precision-focused position wasn't contested on the facts, only on whether the added complexity is worth it in a busy clinical moment, which nobody fully resolved.